Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: In comparison with CEA

Table 4 Relation between serum CA19-9 and CEA levels and clinicopathologic features of tumors in 35 patients with cholangiocarcinoma (mean ± SD)

	No. of	CA19-9	CEA
	patients	(KU/L)	(μg/L)
Well-differentiated	16	261.67 ± 6.31	34.37 ± 11.29
adenocarcinoma
Moderately-differentiated	12	270.56 ± 4.57	38.42 ± 19.23
adenocarcinoma
Poorly-differentiated	5	302.71 ± 5.81	48.23 ± 23.64
adenocarcinoma
Anaplastic carcinoma	1	468	64
Adenosquamous carcinoma	1	293	27
Perineural infiltration
Positive	23	310.12 ± 7.11a	37.64 ± 10.35b
Negative	10	195.16 ± 6.48	21.28 ± 13.15
Venous invasion
Positive	17	318.49 ± 3.27b	39.78 ± 18.41b
Negative	18	253.08 ± 5.37	29.67 ± 20.13
Lymph node metastasis
Positive	18	345.66 ± 4.23a	46.37 ± 9.46b
Negative	17	265.30 ± 4.58	31.89 ± 16.46

^aP < 0.01, ^bP < 0.05, ^cP < 0.05 vs negative group.